Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the
world. In many countries, the mortality related to lung cancer continues to rise. The outcomes …

Systemic therapy improves the survival and quality of life of patients with advanced stage
non-small cell lung cancer (NSCLC). Several new therapeutic options have emerged for …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Purpose: Epidermal growth factor receptor (EGFR) is commonly overexpressed in lung
cancer. Cetuximab is a chimeric mouse-human antibody targeted against EGFR. Compared …

ContextRandomized trials have demonstrated that adding a drug to a single-agent or to a 2-
agent regimen increased the tumor response rate in patients with advanced non–small-cell …

BACKGROUND: Palliative chemotherapy is aimed at increasing survival and palliating
symptoms. However, the response rate to first‐line chemotherapy in patients with nonsmall …

Purpose: No chemotherapy regimen, including the widely used combination of
gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic …

Evidence suggests that platinum-based regimens confer a better survival in patients with
non-small cell lung carcinoma (NSCLC). However, evidence is lacking regarding the …

Introduction Non-small cell lung cancer (NSCLC) frequently presents at an incurable stage,
and a majority of patients will be considered for palliative chemotherapy at some point in …